We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

15 hedge funds and large institutions have $13.6M invested in Oramed Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,209% more capital invested

Capital invested by funds: $216K → $13.6M (+$13.4M)

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

114% more funds holding

Funds holding: 7 → 15 (+8)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
15
Holders Change
+8
Holders Change %
+114.29%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
+$6.09M
2
GIM
Greylin Investment Management
Virginia
+$398K
3
Morgan Stanley
Morgan Stanley
New York
+$92K
4
GT
Glenmede Trust
Pennsylvania
+$7.7K
5
HCM
Highlander Capital Management
New Jersey
+$7.7K

Top Sellers

Rank Fund Capital Flow
1
PM
Platinum Management
New York
-$165K
2
TRCT
Tower Research Capital (TRC)
New York
-$17.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWMDMG
1
Austin W. Marxe & David M. Greenhouse
New York
$12.2M +$6.09M +790,000 New
GIM
2
Greylin Investment Management
Virginia
$798K +$398K +51,700 New
TAM
3
Telluride Asset Management
Minnesota
$299K +$149K +19,371 New
Morgan Stanley
4
Morgan Stanley
New York
$184K +$92K +11,941 New
FNBT
5
FineMark National Bank & Trust
Florida
$54K – – –
U
6
UBS
Switzerland
$24K +$7.51K +975 +171%
Wells Fargo
7
Wells Fargo
California
$21K – – –
HCM
8
Highlander Capital Management
New Jersey
$15.4K +$7.7K +1,000 New
GT
9
Glenmede Trust
Pennsylvania
$15K +$7.7K +1,000 New
FNYS
10
First New York Securities
New York
$11K +$5.67K +736 New
HRIA
11
Haberer Registered Investment Advisor
Ohio
$5K – – –
Citigroup
12
Citigroup
New York
$5K +$2.31K +300 New
ASN
13
Advisory Services Network
Georgia
$4K +$2.2K +285 New
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$3K – – –
PM
15
Platinum Management
New York
– -$165K -26,573 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$17.8K -2,313 -99%

ORMP Hedge Fund Activity: Q4 2013 in Review

15 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2013, worth a combined $13.6M — up 6,209% from $216K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ORMP positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Austin W. Marxe & David M. Greenhouse, opening a new position worth an estimated $6.09M. The largest seller was Platinum Management, exiting entirely with an estimated $165K sold.

  • 15 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2013, up from 7 in Q3 2013.
  • Funds reported $13.6M of Oramed Pharmaceuticals stock for Q4 2013, up 6,209% quarter-over-quarter.
  • 9 funds opened new Oramed Pharmaceuticals positions in Q4 2013 and 1 closed out, a net change of +8 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $6.09M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2013 was Platinum Management, an estimated $165K sold.

Based on aggregated 13F filings for Q4 2013.